ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation

Haydee Martínez, Michelle Nagurney, Zi Xuan Wang, Charles G Eberhart, Christopher M Heaphy, Mark T. Curtis, Fausto J Rodriguez

Research output: Contribution to journalArticle

Abstract

Pineal parenchymal tumors are rare neoplasms, ranging from WHO Grade I to IV. There are few studies characterizing the molecular profiles of these tumors. ATRX alterations are strongly associated with the presence of the alternative lengthening of telomeres (ALT) phenotype, and within the central nervous system they tend to occur in subsets of gliomas, including those with IDH, NF1, or histone (H3 K27M or G34) mutations. Here, we identified ATRX frameshift mutations by next generation sequencing associated with corresponding protein loss in 2 cases of pineal parenchymal tumors of intermediate differentiation (PPTID) developing in a 21-year-old woman and a 64-year-old man. In contrast, we identified partial ATRX loss in 1 pineoblastoma, among 14 pineal parenchymal tumors of various grades (6 pineoblastomas, 4 pineocytomas, and 4 PPTID) using tissue microarrays; ALT was absent in these cases. Evaluating the cBioPortal database, an ATRX mutation was identified in one (of 3 total) PPTIDs analyzed. Thus, ATRX mutations associated with protein loss and ALT develop in a small subset of pineal parenchymal tumors and may be limited to those with intermediate differentiation. The clinical significance of these alterations requires further study.

Original languageEnglish (US)
Pages (from-to)703-708
Number of pages6
JournalJournal of Neuropathology and Experimental Neurology
Volume78
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pinealoma
Mutation
Telomere Homeostasis
Frameshift Mutation
Glioma
Histones
Neoplasms
Proteins
Central Nervous System
Databases
Phenotype

Keywords

  • Alternative lengthening of telomeres
  • ATRX
  • Pineal
  • Pineal parenchymal tumor
  • Pineal parenchymal tumors of intermediate differentiation (PPTID)

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation. / Martínez, Haydee; Nagurney, Michelle; Wang, Zi Xuan; Eberhart, Charles G; Heaphy, Christopher M; Curtis, Mark T.; Rodriguez, Fausto J.

In: Journal of Neuropathology and Experimental Neurology, Vol. 78, No. 8, 01.01.2019, p. 703-708.

Research output: Contribution to journalArticle

@article{2fc1caca5a674e658fc9e70cd524bf9b,
title = "ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation",
abstract = "Pineal parenchymal tumors are rare neoplasms, ranging from WHO Grade I to IV. There are few studies characterizing the molecular profiles of these tumors. ATRX alterations are strongly associated with the presence of the alternative lengthening of telomeres (ALT) phenotype, and within the central nervous system they tend to occur in subsets of gliomas, including those with IDH, NF1, or histone (H3 K27M or G34) mutations. Here, we identified ATRX frameshift mutations by next generation sequencing associated with corresponding protein loss in 2 cases of pineal parenchymal tumors of intermediate differentiation (PPTID) developing in a 21-year-old woman and a 64-year-old man. In contrast, we identified partial ATRX loss in 1 pineoblastoma, among 14 pineal parenchymal tumors of various grades (6 pineoblastomas, 4 pineocytomas, and 4 PPTID) using tissue microarrays; ALT was absent in these cases. Evaluating the cBioPortal database, an ATRX mutation was identified in one (of 3 total) PPTIDs analyzed. Thus, ATRX mutations associated with protein loss and ALT develop in a small subset of pineal parenchymal tumors and may be limited to those with intermediate differentiation. The clinical significance of these alterations requires further study.",
keywords = "Alternative lengthening of telomeres, ATRX, Pineal, Pineal parenchymal tumor, Pineal parenchymal tumors of intermediate differentiation (PPTID)",
author = "Haydee Mart{\'i}nez and Michelle Nagurney and Wang, {Zi Xuan} and Eberhart, {Charles G} and Heaphy, {Christopher M} and Curtis, {Mark T.} and Rodriguez, {Fausto J}",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/jnen/nlz050",
language = "English (US)",
volume = "78",
pages = "703--708",
journal = "Journal of Neuropathology and Experimental Neurology",
issn = "0022-3069",
number = "8",

}

TY - JOUR

T1 - ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation

AU - Martínez, Haydee

AU - Nagurney, Michelle

AU - Wang, Zi Xuan

AU - Eberhart, Charles G

AU - Heaphy, Christopher M

AU - Curtis, Mark T.

AU - Rodriguez, Fausto J

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pineal parenchymal tumors are rare neoplasms, ranging from WHO Grade I to IV. There are few studies characterizing the molecular profiles of these tumors. ATRX alterations are strongly associated with the presence of the alternative lengthening of telomeres (ALT) phenotype, and within the central nervous system they tend to occur in subsets of gliomas, including those with IDH, NF1, or histone (H3 K27M or G34) mutations. Here, we identified ATRX frameshift mutations by next generation sequencing associated with corresponding protein loss in 2 cases of pineal parenchymal tumors of intermediate differentiation (PPTID) developing in a 21-year-old woman and a 64-year-old man. In contrast, we identified partial ATRX loss in 1 pineoblastoma, among 14 pineal parenchymal tumors of various grades (6 pineoblastomas, 4 pineocytomas, and 4 PPTID) using tissue microarrays; ALT was absent in these cases. Evaluating the cBioPortal database, an ATRX mutation was identified in one (of 3 total) PPTIDs analyzed. Thus, ATRX mutations associated with protein loss and ALT develop in a small subset of pineal parenchymal tumors and may be limited to those with intermediate differentiation. The clinical significance of these alterations requires further study.

AB - Pineal parenchymal tumors are rare neoplasms, ranging from WHO Grade I to IV. There are few studies characterizing the molecular profiles of these tumors. ATRX alterations are strongly associated with the presence of the alternative lengthening of telomeres (ALT) phenotype, and within the central nervous system they tend to occur in subsets of gliomas, including those with IDH, NF1, or histone (H3 K27M or G34) mutations. Here, we identified ATRX frameshift mutations by next generation sequencing associated with corresponding protein loss in 2 cases of pineal parenchymal tumors of intermediate differentiation (PPTID) developing in a 21-year-old woman and a 64-year-old man. In contrast, we identified partial ATRX loss in 1 pineoblastoma, among 14 pineal parenchymal tumors of various grades (6 pineoblastomas, 4 pineocytomas, and 4 PPTID) using tissue microarrays; ALT was absent in these cases. Evaluating the cBioPortal database, an ATRX mutation was identified in one (of 3 total) PPTIDs analyzed. Thus, ATRX mutations associated with protein loss and ALT develop in a small subset of pineal parenchymal tumors and may be limited to those with intermediate differentiation. The clinical significance of these alterations requires further study.

KW - Alternative lengthening of telomeres

KW - ATRX

KW - Pineal

KW - Pineal parenchymal tumor

KW - Pineal parenchymal tumors of intermediate differentiation (PPTID)

UR - http://www.scopus.com/inward/record.url?scp=85072685190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072685190&partnerID=8YFLogxK

U2 - 10.1093/jnen/nlz050

DO - 10.1093/jnen/nlz050

M3 - Article

C2 - 31225581

AN - SCOPUS:85072685190

VL - 78

SP - 703

EP - 708

JO - Journal of Neuropathology and Experimental Neurology

JF - Journal of Neuropathology and Experimental Neurology

SN - 0022-3069

IS - 8

ER -